[go: up one dir, main page]

AU2643288A - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
AU2643288A
AU2643288A AU26432/88A AU2643288A AU2643288A AU 2643288 A AU2643288 A AU 2643288A AU 26432/88 A AU26432/88 A AU 26432/88A AU 2643288 A AU2643288 A AU 2643288A AU 2643288 A AU2643288 A AU 2643288A
Authority
AU
Australia
Prior art keywords
pharmaceutical compositions
buprenorphine
naltrexone
opiate
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU26432/88A
Other versions
AU613993B2 (en
Inventor
John William Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reckitt Benckiser Healthcare UK Ltd
Original Assignee
Reckitt Benckiser Healthcare UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt Benckiser Healthcare UK Ltd filed Critical Reckitt Benckiser Healthcare UK Ltd
Publication of AU2643288A publication Critical patent/AU2643288A/en
Application granted granted Critical
Publication of AU613993B2 publication Critical patent/AU613993B2/en
Assigned to RECKITT & COLMAN PRODUCTS LIMITED reassignment RECKITT & COLMAN PRODUCTS LIMITED Alteration of Name(s) in Register under S187 Assignors: RECKITT & COLMAN PRODUCTS LIMITED
Assigned to RECKITT BENCKISER HEALTHCARE (UK) LIMITED reassignment RECKITT BENCKISER HEALTHCARE (UK) LIMITED Request to Amend Deed and Register Assignors: RECKITT & COLMAN PRODUCTS LIMITED
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Glass Compositions (AREA)

Abstract

A pharmaceutical composition in sublingual unit dosage form for maintenance treatment of opiate addicts comprising from 2 to 8mg buprenorphine and an amount of naltrexone sufficient to substantially attenuate the euphorigenic effect of the buprenorphine when injected and to provide greater opiate blocking effect than that of naltrexone alone.
AU26432/88A 1987-12-03 1988-12-02 Pharmaceutical compositions Expired AU613993B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8728294 1987-12-03
GB878728294A GB8728294D0 (en) 1987-12-03 1987-12-03 Treatment compositions

Publications (2)

Publication Number Publication Date
AU2643288A true AU2643288A (en) 1989-06-08
AU613993B2 AU613993B2 (en) 1991-08-15

Family

ID=10627937

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26432/88A Expired AU613993B2 (en) 1987-12-03 1988-12-02 Pharmaceutical compositions

Country Status (9)

Country Link
US (1) US4935428A (en)
EP (1) EP0319243B1 (en)
AT (1) ATE58060T1 (en)
AU (1) AU613993B2 (en)
DE (1) DE3861014D1 (en)
GB (1) GB8728294D0 (en)
IE (1) IE61198B1 (en)
NZ (1) NZ227083A (en)
ZA (1) ZA888885B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362194B1 (en) 1992-09-21 2002-03-26 Albert Einstein College Of Medicine Of Yeshiva University Method and simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
AU782475B2 (en) * 1993-07-27 2005-08-04 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
CA2063340A1 (en) * 1991-11-12 1993-05-13 Mahmoud Cherif Assaad Biased pneumatic tire having a belt structure with six annular layers
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
ATE183926T1 (en) * 1993-09-29 1999-09-15 Alza Corp SKIN PERMEABILITY INCREASE CONSISTING OF MONOGLYCERIDE/LACTATE ESTERS
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
DK0914097T3 (en) * 1996-03-12 2002-04-29 Alza Corp Composition and dosage form comprising opioid antagonist
CA2278137A1 (en) * 1997-01-13 1998-07-16 Alan R. Tripp Opiate antagonist implant and process of preparation therefor
US6228863B1 (en) 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
RU2241458C2 (en) * 1997-12-22 2004-12-10 Эро-Селтик, С.А. Combinations of agonist/antagonist for opioid
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6007841A (en) * 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
BR0013650A (en) 1999-08-27 2002-05-07 Southern Res Inst Injectable compositions of buprenorphine microparticles and their use
AU1807401A (en) * 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
DK2092936T3 (en) * 2000-02-08 2013-06-17 Euro Celtique Sa Oral opioid agonist formulations secured against forgery
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
ES2361148T3 (en) 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. DOSAGE FORM OF ABUSE RESISTANT CONTROLLED OPIOID OPTION.
WO2003004033A1 (en) * 2001-07-06 2003-01-16 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
DE60219478T2 (en) * 2001-07-06 2008-01-03 Endo Pharmaceuticals Inc. ORAL GIVEN OF 6-HYDROXY-OXYMORPHONE AS ANALGETIC
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
JP4736323B2 (en) * 2001-07-13 2011-07-27 アークレイ株式会社 Puncture element integrated body for concentration measuring device provided with analysis tool, and body fluid collection tool
SI1416842T1 (en) * 2001-07-18 2009-06-30 Euro Celtique Sa Pharmaceutical combinations of oxycodone and naloxone
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
PT1414451E (en) 2001-08-06 2009-07-31 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030091635A1 (en) * 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
DE20321531U1 (en) 2002-04-05 2007-11-22 Euro-Celtique S.A. A shelf stable pharmaceutical preparation comprising oxycodone and naloxone
CA2496454A1 (en) 2002-04-23 2003-11-06 Alza Corporation Transdermal analgesic systems with reduced abuse potential
US7157102B1 (en) 2002-05-31 2007-01-02 Biotek, Inc. Multi-layered microcapsules and method of preparing same
NZ536965A (en) * 2002-05-31 2007-02-23 Titan Pharmaceuticals Inc Nonerodible polymeric matrix with buprenorphine encapsulated for the treatment of opiate addiction and pain
US7041320B1 (en) 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods
SI1610791T1 (en) 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20050038062A1 (en) * 2003-04-14 2005-02-17 Burns Lindsay H. Methods and materials for the treatment of pain comprising opioid antagonists
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
KR20060120678A (en) 2003-10-30 2006-11-27 알자 코포레이션 Percutaneous analgesic system with reduced likelihood of abuse
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
WO2006058029A2 (en) * 2004-11-22 2006-06-01 Woolhandler Robert A Method of treating opioid dependency
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
DK1895994T3 (en) * 2005-05-13 2010-12-20 Alza Corp Multilayer drug delivery system with barrier against reservoir material flow
ZA200807571B (en) 2006-03-01 2009-08-26 Ethypharm Sa Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
GB0606124D0 (en) * 2006-03-28 2006-05-03 Reckitt Benckiser Healthcare Buprenorphine derivatives and uses thereof
US20070278289A1 (en) * 2006-05-31 2007-12-06 Toshiba Tec Kabushiki Kaisha Payment adjusting apparatus and program therefor
KR20150029762A (en) 2006-06-19 2015-03-18 알파마 파머슈티컬스 엘엘씨 Pharmaceutical compositions
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
PT2101740E (en) 2006-12-04 2013-12-23 Orexo Ab New non-abusable pharmaceutical composition comprising opioids
US20080199407A1 (en) 2007-02-15 2008-08-21 Slater Kenneth C Drug Detoxification Protocol Using Microdosing
GB2447014A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20110177133A1 (en) * 2008-07-07 2011-07-21 Michael Hopp Use of opioid antagonists for treating urinary retention
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US20130071477A1 (en) 2011-09-19 2013-03-21 Orexo Ab New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
MX2016000810A (en) 2013-07-23 2016-08-05 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362194B1 (en) 1992-09-21 2002-03-26 Albert Einstein College Of Medicine Of Yeshiva University Method and simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US7026329B2 (en) 1992-09-21 2006-04-11 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
AU782475B2 (en) * 1993-07-27 2005-08-04 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists

Also Published As

Publication number Publication date
ATE58060T1 (en) 1990-11-15
EP0319243B1 (en) 1990-11-07
ZA888885B (en) 1989-08-30
GB8728294D0 (en) 1988-01-06
IE883595L (en) 1989-06-03
NZ227083A (en) 1991-02-26
EP0319243A1 (en) 1989-06-07
US4935428A (en) 1990-06-19
AU613993B2 (en) 1991-08-15
DE3861014D1 (en) 1990-12-13
IE61198B1 (en) 1994-10-19

Similar Documents

Publication Publication Date Title
AU2643288A (en) Pharmaceutical compositions
AU4806197A (en) Method and potentiated composition for treating migraine
AU4534593A (en) Compositions and methods for enhanced drug delivery
GB2263115B (en) Composition for dental restoration
GR890100636A (en) Analgesic compositions
BG102668A (en) Application of ppar-alpha and prar-gamma antagonist for the treatment of syndrome x
AU4032989A (en) Method and compositions for the treatment and prevention of septic shock
GB9208339D0 (en) Treatment composition
GR3022997T3 (en) Synergistic therapeutic compositions and methods
AU1110192A (en) Method and composition for treating reperfusion injury
EP0591303A4 (en) Methods and compositions for treating malaria and other diseases
GR3022995T3 (en) Pharmaceutical composition consisting of flupirtin and morphine for the treatment of pain and to avoid a morphine addiction
IL88745A (en) Mixed compositions for treating hypercholesterolemia
ZA834563B (en) Synergistic compositions of nalbuphine and non-narcotic analgesic compounds
EP0357311A3 (en) Motor fuel additive and ori-inhibited motor fuel composition
IL91928A0 (en) Pharmaceutical compositions containing prolactin and methods for the use threof
GB2222768B (en) Analgesic compounds and compositions
PH24723A (en) Device and composition for treatment of the gums
AU3222893A (en) Therapeutic composition and method for preventing reperfusion injury
GR900300082T1 (en) Use of dapiprazole for the manufacture of a pharmaceutical composition inhibiting the development of tolerance in the analgesic treatment with morphine
AU2434992A (en) Methods and compositions for treating sunburns
AU1594283A (en) Synergistic compositions of nalbuphine and non-narcotic analgesic compounds
ZA881170B (en) Compositions and methods for treating wood
IL104756A0 (en) Composition for the treatment of glaucoma
GB8924413D0 (en) Oil waste treatment compositions

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: RECKITT BENCKISER HEALTHCARE (UK) LIMITED

Free format text: FORMER NAME WAS: RECKITT AND COLMAN PRODUCTS LIMITED